SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

Recall Crypto is trending due to high volume and discussions around its recent ICO and potential utility in AI and DeFi, with some comparing it to "OpenAI meets DeFi". The community is actively debating whether it's a promising opportunity or a potential rug pull, while also exploring its connections to other altcoins and pump.fun.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending as investors discuss its Vector AI platform and potential revenue impact, with community members analyzing its competitive positioning against companies like AppLovin. A recent analyst downgrade has spurred debate about market sentiment and the stock's short-term trajectory, while some express long-term confidence in the company's turnaround and growth prospects. Discussions also include potential catalysts, such as earnings reports and possible partnerships, that could drive future stock performance.

Pepek Philippe is a whimsical meme coin inspired by the lavish lifestyle of billionaire frogs flaunting luxury watches. This project humorously showcases the world of amphibious elites who enjoy opulence, fine dining, private jets, beautiful women, fast cars, mansions, and, of course, top-tier timepieces. The coin celebrates this absurdly rich lifestyle, blending humor with luxury culture to create a fun, engaging crypto experience.

Pepek Philippe

Pepek Philippe ($PEPEK) is trending as community members discuss its potential as the next PEPE, while others are warning of a potential rug pull. Conversations revolve around quick entries and exits, with some users promoting the coin's availability on Phantom Wallet, and others expressing concerns about low liquidity.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab ($GTLB) is trending amid mixed sentiment following earnings, with debates around its AI strategy and competition with GitHub; key is if it can hold above 50. Recent discussions highlight both positive aspects, like high customer satisfaction and revenue growth, and concerns, including lowered price targets and a CFO exit.

PAX Gold (PAXG) is an asset-backed token where one token should represent one fine troy ounce of a London Good Delivery gold bar, stored in professional vault facilities. Anyone who owns PAXG has ownership rights to that gold under the custody of Paxos Trust Company. Since PAXG represents physical gold, its value is tied directly to the real-time market value of that physical gold.  PAXG gives customers the benefits of actual physical ownership of specific gold bars with the speed and mobility of a digital asset. Customers are able to have fractional ownership of physical bars. On the Paxos platform, customers can convert their tokens to allocated gold, unallocated gold, or fiat currency (and vice versa) quickly and efficiently, reducing their exposure to settlement risk. PAXG is also available for trading on Paxos’ itBit exchange. PAXG will also be available on other crypto-asset exchanges, wallets, lending platforms and elsewhere within the crypto ecosystem.   At any time, PAXG holders can lookup the serial number, value and physical characteristics of their vaulted gold just by entering their Ethereum wallet address on the PAXG lookup tool on Paxos.com/paxgold.

PAX Gold

PAX Gold is trending as investors explore safe-haven assets amidst broader market uncertainty and crypto volatility, with some community members viewing it as a hedge against traditional financial systems. Discussions revolve around its role as 'digital gold' and its potential to outperform Bitcoin in the current climate. Community members also discuss the best platforms for holding PAXG.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

CVM is trending as investors closely monitor developments surrounding its Breakthrough Medicine Designation application in Saudi Arabia, with the review timeline nearing conclusion. Community discussions revolve around the potential for rapid approval and commercialization in the MENA region, aligning with Saudi Vision 2030's biotech ambitions. Some express frustration with the company's history and management, while others remain optimistic about Multikine's potential impact on cancer treatment.

Basic Attention Token (BAT) is an open-source, decentralized ad exchange platform built on Ethereum platform. Basic Attention Token held an initial coin offering on May 31, 2017 for its eponymous ERC-20 utility token, raising approximately $35M USD at the time in less than 30 seconds. The Basic Attention Token aims to fix digital advertising, which is broken, fraudulent and opaque.   Basic Attention Token work by having advertisers pay BAT to website publishers for the attention of users. The BAT token is designed to correctly value and price user attention within the platform. The Basic Attention Token comprises various components, including attention measurement systems, analytics dashboards and machine learning algorithms. Integration of BAT into a given host application involves implementing BAT Ads, a system that matches and displays ads to users based on locally stored data. Ad targeting is performed wholly on-device, removing the need for third-party tracking. BAT is focused on the Brave browser. Brave is an open-source, privacy-centered browser designed to block trackers and malware. It utilizes blockchain technology to anonymously and securely track user attention, which translates into rewards for publishers.  A user's attention, meaning his or her focused mental engagement on digital content like advertisements, is logged through Brave. The makers of BAT indicate that the user's private data and tracking information is stored only on the user's device, ensuring that it is anonymous and private.  Created back in 2016, the Basic Attention Token has one of the biggest names behind it, that of Brendan Eich, the creator of JavaScript and the legendary co-founder of Mozilla. Other noteworthy team members include Brian Bondy, lead developer and co-founder of Brave and Scott Locklin, senior engineer, and co-founder of Kerf Software."  Basic Attention Token is created by the team that built the Brave browser, an open-source, privacy-focused browser that blocks ads and trackers. The browser measures user attention and rewards publishers for users attention.   Use the Brave browser to protect your privacy and support CoinGecko at the same time: https://brave.com/coi600

Basic Attention Token

Basic Attention Token is trending as the community discusses its real-world utility through the Brave browser and potential for growth in the Web3 space. Chatter on 4chan is also contributing to the increased interest. Some users are speculating on partnerships and future price potential given Brave's growing user base.

Telefonaktiebolaget LM Ericsson engages in the provision of telecommunications equipment and related services to mobile and fixed network operators. It operates through the following segments: Networks, Cloud Software, Services, Enterprise, and Other. The Networks segment supports all radio-access technologies and offers hardware, software and related services for both radio access and transport. The Cloud Software segment offers solutions for core networks, business and operational support systems, network design and optimization, and managed network services. The Other segment refers to the media business and other non-allocated business. Segment-level information has also been presented to Other. The company was founded by Lars Magnus Ericsson in 1876 and is headquartered in Kista, Sweden.

Telefonaktiebolaget L M Ericsson - ADR

LM Ericsson Telephone Co.

ERIC is trending as discussions revolve around potential upside and trading strategies, driven by observed data and technical analysis suggesting room for growth. Community members are highlighting LEAP options, breakout patterns, and following specific traders for potential plays. Additionally, news regarding earnings, partnerships, and AI advancements in enterprise 5G are contributing to the heightened interest.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending as investors digest mixed signals, including a potential crypto trading rollout and analyst rating adjustments. Community chatter revolves around strong earnings potential versus tariff-related economic uncertainty and concerns about near-term IPO activity. Trading volume and options activity suggest anticipation of catalysts and potential volatility for the financial giant.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

DCTH is trending due to discussions around recent financial guidance and potential impacts from the Medicaid National Drug Rebate Agreement. The community is focused on the potential for a revenue shortfall in the next quarter, while others see opportunity in the long-term growth and CHOPIN trial data. Some traders are highlighting insider buying and positive news sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Equity

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 


Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include KALA, Graham, Arq and Hawkins

KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company announced the resignation of CEO Mark Iwicki.President Todd Bazemore has been named interim CEO, while Iwicki will remain as chair of the board.&nbsp;Iwicki, who has led Kala for nearly a decade, oversaw multiple phases of drug development.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/KALA_sentiment_and_message_volume_on_Feb_12_cdc55fd016.png" alt="KALA sentiment and message volume on Feb 12.png" width="1318" height="324"><figcaption>KALA sentiment and message volume on Feb 12 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the steep selloff, retail traders on Stocktwits believe the market reaction is excessive, as evidenced by the 'extremely bullish' sentiment score.&nbsp;One user argued that Iwicki's departure "is the best thing possible for this company" and could signal a potential sale of the company after Kala's upcoming pipeline update.<stembedurl>https://stocktwits.com/Stmkr/message/603965500</stembedurl><stembedurl>https://stocktwits.com/Sammysums/message/603977842</stembedurl>Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects, a condition that can lead to vision loss.&nbsp;The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, while its MSC-S platform is in preclinical studies for retinal degenerative conditions like Retinitis Pigmentosa and Stargardt Disease.At the end of 2024, Kala raised approximately $10.8 million through a private placement of common shares and Series I convertible preferred stock with institutional investors.The company is expected to report fourth-quarter earnings in March. Wall Street projects an adjusted loss per share of $2.28, down from $3.62 a year ago, on no revenue.Kala shares are down just 2.2% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.

KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44...

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

KALA
Kala Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KALA News

KALAKala Pharmaceuticals Inc